Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889382 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
A Phase 1 study of Ovarian Cancer and Solid Tumors, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT00889382 is a Phase 1 study of Ovarian Cancer and Solid Tumors that has completed, run by Astellas Pharma. The registered enrollment target is 152 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00889382, a Phase 1 study of Ovarian Cancer and Solid Tumors, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG OSI-906
Study Locations (20)
Western Australia
- St. John of God Hospital, Bunbury - Bunbury
- Sir Charles Gairdner Hospital - Perth
- St. John of Gog Hospital, Subiaco - Subiaco
North Carolina
- Blumenthal Cancer Center - Main - Charlotte
- Duke University Medical Center - Durham
Victoria
- Frankston Hospital - Frankston
- Border Medical Oncology - Wodonga
Ontario
- Juravinski Cancer Center - Hamilton
- Princess Margaret Hospital - Toronto
Arizona
- Mayo Clinic - Scottsdale
California
- Department of Obstetrics and Gynecology, University of California, Irvine - Orange
Indiana
- Horizon Oncology Center - Lafayette
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2009-08-05 |
| Est. Completion | 2014-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889382
The ClinicalTrials.gov registry entry for NCT00889382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00889382 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Western Australia, North Carolina, Victoria.
Frequently Asked Questions
What is clinical trial NCT00889382 about?
NCT00889382 is a clinical study titled "A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)". This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
What is the current status of trial NCT00889382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2009-08-05. Estimated completion is 2014-08-25.
What conditions does trial NCT00889382 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumors.
What interventions are being tested in trial NCT00889382?
The interventions under investigation include: Paclitaxel (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT00889382?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00889382 being conducted?
This trial has 20 study locations across Arizona, California, Indiana, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.